论文部分内容阅读
目的观察促性腺激素释放激素类似物(GnRH-A)治疗女童特发性中枢性性早熟(ICPP)的临床疗效。方法12例ICPP女童用GnRH-A治疗,于治疗前和治疗6个月末观察第二性征、生长速率(GV),B超检查子宫、卵巢大小,X线片推断骨龄(BA),检测血清雌二醇(E2)、促黄体素释放素(LHRH)激发试验以及预测成人终身高(PAH)的变化。结果治疗后乳房退缩,子宫、卵巢容积缩小,LHRH激发试验显示促黄体生成素(LH)、卵泡刺激素(FSH)基值和峰值均显著降低,E2恢复到青春期前水平,骨龄进展缓慢,BA/CA(实际年龄)比值下降,预测成人终身高提高。结论GnRH-A能有效地抑制性征发育和骨龄增长,并改善预测成人终身高。
Objective To observe the clinical efficacy of gonadotropin-releasing hormone analogue (GnRH-A) in the treatment of idiopathic central precocious puberty (ICPP) in girls. Methods Twelve girls with ICPP were treated with GnRH-A. The second sexual characteristics and the growth rate (GV) were observed before treatment and at the end of 6 months of treatment. The uterus, ovarian size, Estradiol (E2), luteinizing hormone releasing hormone (LHRH) provocation test and predicting the change of adult height (PAH). Results After treatment, the breasts retreated and the volume of the uterus and ovary decreased. LHRH test showed that the basal and peak values of luteinizing hormone (LH) and follicle stimulating hormone (FSH) were significantly decreased. E2 returned to the level of preadhesia and bone age progressed slowly. BA / CA (actual age) ratio decreased adult height prediction is increased. Conclusion GnRH-A can effectively inhibit the development of sexual signs and bone age, and improve the prediction of adult longevity.